The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges
Open accessAbstract
Direct oral anticoagulants ( DOAC s) have quickly become attractive alternatives to the long‐standing standard of care in anticoagulation, vitamin K antagonist. DOAC s are indicated for prevention and treatment of several cardiovascular conditions. Since the first approval in 2010, DOAC s have emerged as leading therapeutic alternatives that provide both clinicians and patients with more effective, safe, and convenient treatment options in thromboembolic settings. With the expanding role of DOAC s, clinicians are faced with increasingly complex decisions relating to appropriate agent, duration of treatment, and use in special populations. This review will provide an overview of DOAC s and act as a practical reference for clinicians to optimize DOAC use among common challenging scenarios. Topics addressed include (1) appropriate indications; (2) use in patients with specific comorbidities; (3) monitoring parameters; (4) transitioning between anticoagulant regimens; (5) major drug interactions; and (6) cost considerations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,115
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62343-0 · Cited by 5,051 · cited 3×
“Three different types of drug interactions need to be evaluated when managing DOAC therapy: (1) agents affecting renal clearance, (2) agents affecting hepatic clearance, and (3) agents concurrently affecting hemostasis.”
BackgroundNishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Fleisher, L. A., Jneid, H., Mack, M. J., McLeod, C. J., O’Gara, P. T., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.03.011 · Cited by 3,339
Lee, A. Y. Y., Levine, M. N., Baker, R. I., Bowden, C., Kakkar, A. K., Prins, M., Rickles, F. R., Julian, J. A., Haley, S., Kovacs, M. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025313 · Cited by 2,534
Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Fleisher, L. A., Jneid, H., Mack, M. J., McLeod, C. J., O’Gara, P. T., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000503 · Cited by 2,497
Rivaroxaban with or without aspirin in stable cardiovascular disease
Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O., Diaz, R., Alings, M., Lonn, E. M., Anand, S. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709118 · Cited by 2,438
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
January, C. T., Wann, L. S., Calkins, H., Chen, L. Y., Cigarroa, J. E., Cleveland, J. C., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., Furie, K. L., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.011 · Cited by 2,205
Steffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy136 · Cited by 2,123
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000040 · Cited by 2,056
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
Mega, J. L., Braunwald, E., Wiviott, S. D., Bassand, J.-P., Bhatt, D. L., Bode, C., Burton, P., Cohen, M., Cook-Bruns, N., Fox, K. A. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112277 · Cited by 1,897
Smith, S. C., Benjamin, E. J., Bonow, R. O., Braun, L. T., Creager, M. A., Franklin, B. A., Gibbons, R. J., Grundy, S. M., Hiratzka, L. F., Jones, D. W., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318235eb4d · Cited by 1,759
Levine, G. N., Bates, E. R., Bittl, J. A., Brindis, R. G., Fihn, S. D., Fleisher, L. A., Granger, C. B., Lange, R. A., Mack, M. J., Mauri, L., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.513 · Cited by 1,641
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Raskob, G. E., van Es, N., Verhamme, P., Carrier, M., Di Nisio, M., Garcia, D., Grosso, M. A., Kakkar, A. K., Kovacs, M. J., Mercuri, M. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1711948 · Cited by 1,633
Prevention of bleeding in patients with atrial fibrillation undergoing PCI
Gibson, C. M., Mehran, R., Bode, C., Halperin, J., Verheugt, F. W., Wildgoose, P., Birmingham, M., Ianus, J., Burton, P., van Eickels, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611594 · Cited by 1,590
Dabigatran versus warfarin in patients with mechanical heart valves
Eikelboom, J. W., Connolly, S. J., Brueckmann, M., Granger, C. B., Kappetein, A. P., Mack, M. J., Blatchford, J., Devenny, K., Friedman, J., Guiver, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300615 · Cited by 1,506
Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation
Cannon, C. P., Bhatt, D. L., Oldgren, J., Lip, G. Y. H., Ellis, S. G., Kimura, T., Maeng, M., Merkely, B., Zeymer, U., Gropper, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708454 · Cited by 1,383
Apixaban for Extended Treatment of Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1207541 · Cited by 1,366
Young, A. M., Marshall, A., Thirlwall, J., Chapman, O., Lokare, A., Hill, C., Hale, D., Dunn, J. A., Lyman, G. H., Hutchinson, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.8034 · Cited by 1,348
Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation
Lopes, R. D., Heizer, G., Aronson, R., Vora, A. N., Massaro, T., Mehran, R., Goodman, S. G., Windecker, S., Darius, H., Li, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817083 · Cited by 1,228
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
Agnelli, G., Becattini, C., Meyer, G., Muñoz, A., Huisman, M. V., Connors, J. M., Cohen, A., Bauersachs, R., Brenner, B., Torbicki, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915103 · Cited by 1,067
Antithrombotic Therapy for Atrial Fibrillation
Lip, G. Y. H., Banerjee, A., Boriani, G., Chiang, C. E., Fargo, R., Freedman, B., Lane, D. A., Ruff, C. T., Turakhia, M., Werring, D., et al. (2018) · Chest · doi:10.1016/j.chest.2018.07.040 · Cited by 939
Anand, S. S., Bosch, J., Eikelboom, J. W., Connolly, S. J., Diaz, R., Widimsky, P., Aboyans, V., Alings, M., Kakkar, A. K., Keltai, K., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32409-1 · Cited by 879
Hansen, M. L., Sørensen, R., Clausen, M. T., Fog-Petersen, M. L., Raunsø, J., Gadsbøll, N., Gislason, G. H., Folke, F., Andersen, S. S., Schramm, T. K., et al. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.271 · Cited by 855
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer
Carrier, M., Abou-Nassar, K., Mallick, R., Tagalakis, V., Shivakumar, S., Schattner, A., Kuruvilla, P., Hill, D., Spadafora, S., Marquis, K., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814468 · Cited by 852
Connolly, S. J., Eikelboom, J. W., Bosch, J., Dagenais, G., Dyal, L., Lanas, F., Metsarinne, K., O'Donnell, M., Dans, A. L., Ha, J.-W., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32458-3 · Cited by 754
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
Khorana, A. A., Soff, G. A., Kakkar, A. K., Vadhan-Raj, S., Riess, H., Wun, T., Streiff, M. B., Garcia, D. A., Liebman, H. A., Belani, C. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814630 · Cited by 719
Antithrombotic and Thrombolytic Therapy for Valvular Disease
Whitlock, R. P., Sun, J. C., Fremes, S. E., Rubens, F. D., & Teoh, K. H. (2012) · Chest · doi:10.1378/chest.11-2305 · Cited by 625
Lee, A. Y. Y., Kamphuisen, P. W., Meyer, G., Bauersachs, R., Janas, M. S., Jarner, M. F., Khorana, A. A., & for the CATCH Investigators (2015) · JAMA · doi:10.1001/jama.2015.9243 · Cited by 614
Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial
McBane, R. D., Wysokinski, W. E., Le‐Rademacher, J. G., Zemla, T., Ashrani, A., Tafur, A., Perepu, U., Anderson, D., Gundabolu, K., Kuzma, C., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14662 · Cited by 591
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease
Yasuda, S., Kaikita, K., Akao, M., Ako, J., Matoba, T., Nakamura, M., Miyauchi, K., Hagiwara, N., Kimura, K., Hirayama, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1904143 · Cited by 565
van der Hulle, T., Kooiman, J., den Exter, P. L., Dekkers, O. M., Klok, F. A., & Huisman, M. V. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12485 · Cited by 536
Siontis, K. C., Zhang, X., Eckard, A., Bhave, N., Schaubel, D. E., He, K., Tilea, A., Stack, A. G., Balkrishnan, R., Yao, X., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.035418 · Cited by 492
Yao, X., Shah, N. D., Sangaralingham, L. R., Gersh, B. J., & Noseworthy, P. A. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.03.600 · Cited by 467
Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants
Cuker, A., Siegal, D. M., Crowther, M. A., & Garcia, D. A. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.05.065 · Cited by 449
Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH
Martin, K., Beyer‐Westendorf, J., Davidson, B. L., Huisman, M. V., Sandset, P. M., & Moll, S. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13323 · Cited by 445
Khorana, A. A., Noble, S., Lee, A. Y. Y., Soff, G., Meyer, G., O'Connell, C., & Carrier, M. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14219 · Cited by 442
Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients
Cohen, A. T., Harrington, R. A., Goldhaber, S. Z., Hull, R. D., Wiens, B. L., Gold, A., Hernandez, A. F., & Gibson, C. M. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1601747 · Cited by 441
Doherty, J. U., Gluckman, T. J., Hucker, W. J., Januzzi, J. L., Ortel, T. L., Saxonhouse, S. J., & Spinler, S. A. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.024 · Cited by 441
Kubitza, D., Becka, M., Zuehlsdorf, M., & Mueck, W. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006296058 · Cited by 334
LIESENFELD, K. ‐., LEHR, T., DANSIRIKUL, C., REILLY, P. A., CONNOLLY, S. J., EZEKOWITZ, M. D., YUSUF, S., WALLENTIN, L., HAERTTER, S., & STAAB, A. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04498.x · Cited by 305
Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial
Bohula, E. A., Giugliano, R. P., Ruff, C. T., Kuder, J. F., Murphy, S. A., Antman, E. M., & Braunwald, E. (2016) · Circulation · doi:10.1161/circulationaha.116.022361 · Cited by 290
Upreti, V. V., Wang, J., Barrett, Y. C., Byon, W., Boyd, R. A., Pursley, J., LaCreta, F. P., & Frost, C. E. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12114 · Cited by 269
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease
(2019) · New England Journal of Medicine · doi:10.1056/nejmc1914049 · Cited by 260
Harrington, A. R., Armstrong, E. P., Nolan, P. E., & Malone, D. C. (2013) · Stroke · doi:10.1161/strokeaha.111.000402 · Cited by 259
Raval, A. N., Cigarroa, J. E., Chung, M. K., Diaz-Sandoval, L. J., Diercks, D., Piccini, J. P., Jung, H. S., Washam, J. B., Welch, B. G., Zazulia, A. R., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000477 · Cited by 251
NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018
Streiff, M. B., Holmstrom, B., Angelini, D., Ashrani, A., Bockenstedt, P. L., Chesney, C., Fanikos, J., Fenninger, R. B., Fogerty, A. E., Gao, S., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0084 · Cited by 242
Aspirin: A Historical and Contemporary Therapeutic Overview
Fuster, V., & Sweeny, J. M. (2011) · Circulation · doi:10.1161/circulationaha.110.963843 · Cited by 238
Angiolillo, D. J., Goodman, S. G., Bhatt, D. L., Eikelboom, J. W., Price, M. J., Moliterno, D. J., Cannon, C. P., Tanguay, J.-F., Granger, C. B., Mauri, L., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034722 · Cited by 238
Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010–2017
Zhu, J., Alexander, G. C., Nazarian, S., Segal, J. B., & Wu, A. W. (2018) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2158 · Cited by 229
Anticoagulation Strategies in Patients With Cancer
Mosarla, R. C., Vaduganathan, M., Qamar, A., Moslehi, J., Piazza, G., & Giugliano, R. P. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.017 · Cited by 182
Oral Anticoagulation in Patients With Liver Disease
Qamar, A., Vaduganathan, M., Greenberger, N. J., & Giugliano, R. P. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.023 · Cited by 179
Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation
Kumar, S., Lim, E., Covic, A., Verhamme, P., Gale, C. P., Camm, A. J., & Goldsmith, D. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.1031 · Cited by 175
Carnicelli, A. P., De Caterina, R., Halperin, J. L., Renda, G., Ruff, C. T., Trevisan, M., Nordio, F., Mercuri, M. F., Antman, E., & Giugliano, R. P. (2017) · Circulation · doi:10.1161/circulationaha.116.026714 · Cited by 166
Select Drug-Drug Interactions With Direct Oral Anticoagulants
Wiggins, B. S., Dixon, D. L., Neyens, R. R., Page, R. L., II, & Gluckman, T. J. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.12.068 · Cited by 151
Conway, S. E., Hwang, A. Y., Ponte, C. D., & Gums, J. G. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1884 · Cited by 145
Kushnir, M., Choi, Y. Y., Eisenberg, R. E., Rao, D., Tolu, S. S., Gao, J. Y., Mowrey, W. B., & Billett, H. H. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30086-9 · Cited by 143
Renda, G., Ricci, F., Giugliano, R. P., & Caterina, R. D. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.12.038 · Cited by 139
Ortiz, M. R., Muñiz, J., Miguez, P. R., Roldán, I., Marín, F. R., Esteve‐Pastor, M. A., Cequier, A. R., Martínez‐Sellés, M., Bertoméu, V., Anguita, M. P., et al. (2017) · EP Europace · doi:10.1093/europace/eux316 · Cited by 125
Coleman, C. I., Kreutz, R. H., Sood, N. A., Bunz, T. J., Eriksson, D., Meinecke, A., & Baker, W. L. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.04.013 · Cited by 124
Sanghai, S., Wong, C. H., Wang, Z., Clive, P. H., Tran, W., Waring, M. E., Goldberg, R. J., Hayward, R., Saczynski, J. S., & McManus, D. D. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014108 · Cited by 123
Durães, A. R., Roriz, P. D. S., Nunes, B. D. A., Albuquerque, F. P. E., de Bulhões, F. V., Fernandes, A. M. S., & Aras, R. (2016) · Drugs in R&D · doi:10.1007/s40268-016-0124-1 · Cited by 116
Guimarães, P. O., Pokorney, S. D., Lópes, R. D., WOJDYLA, D. M., Gersh, B. J., Giczewska, A., Carnicelli, A., Lewis, B. S., Hanna, M., Wallentin, L. C., et al. (2019) · Clinical Cardiology · doi:10.1002/clc.23178 · Cited by 115
Tanigawa, T., Kaneko, M., Hashizume, K., Kajikawa, M., Ueda, H., Tajiri, M., Paolini, J. F., & Mueck, W. (2012) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-12-rg-034 · Cited by 114
Douketis, J. D., Spyropoulos, A. C., Anderson, J., Arnold, D. M., Bates, S. M., Blostein, M. D., Carrier, M., Caprini, J. A., Clark, N. P., Coppens, M., et al. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-08-0553 · Cited by 107
Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Low Body Weight
Lee, S., Choi, E., Park, C. S., Han, K., Jung, J., Oh, S., & Lip, G. Y. H. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.051 · Cited by 95
Vaduganathan, M., Bhatt, D. L., Cryer, B., Liu, Y., Hsieh, W.-H., Doros, G. D., Cohen, M. C., Lanas, Á., Schnitzer, T. J., Shook, T., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.068 · Cited by 94
Piran, S., Traquair, H., Chan, N., Bhagirath, V. C., & Schulman, S. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12146 · Cited by 94
Rose, D., & Bar, B. (2018) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2018.04.004 · Cited by 90
Kido, K., & Ngorsuraches, S. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018796604 · Cited by 86
Murata, N., Okumura, Y., Yokoyama, K., Matsumoto, N., Tachibana, E., Kuronuma, K., Oiwa, K., Matsumoto, M., Kojima, T., Hanada, S., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-18-0991 · Cited by 83
Kapoor, A., Ellis, A. G., Shaffer, N., Gurwitz, J. H., Chandramohan, A., Saulino, J., Ishak, A. M., Okubanjo, T., Hylek, E. M., Trikalinos, T., et al. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13566 · Cited by 79
Boonyawat, K., Caron, F., Li, A., Chai‐Adisaksopha, C., Lim, W., Iorio, A., Lópes, R. D., Garcia, D. A., & Crowther, M. A. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13701 · Cited by 78
Coons, J. C., Albert, L., Bejjani, A., & Iasella, C. J. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2369 · Cited by 76
Chokesuwattanaskul, R., Thongprayoon, C., Tanawuttiwat, T., Kaewput, W., Pachariyanon, P., & Cheungpasitporn, W. (2018) · Pacing and Clinical Electrophysiology · doi:10.1111/pace.13331 · Cited by 74
Efficacy and safety of novel oral anticoagulants in patients with bioprosthetic valves
Yadlapati, A., Groh, C. A., Malaisrie, S. C., Gajjar, M. M., Kruse, J. T., Meyers, S. N., & PASSMAN, R. S. (2015) · Clinical Research in Cardiology · doi:10.1007/s00392-015-0919-z · Cited by 64
Shah, A., Shewale, A. R., Hayes, C. J., & Martin, B. C. (2016) · Stroke · doi:10.1161/strokeaha.115.012325 · Cited by 64
The impact of body weight on rivaroxaban pharmacokinetics
Barsam, S. J., Patel, J. P., Roberts, L. N., Kavarthapu, V., Patel, R., Green, B., & Arya, R. (2017) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12039 · Cited by 52
Attena, E., Mazzone, C., Esposito, F., Parisi, V., Bancone, C., Rago, A., Nigro, G., Sangiuolo, R., Onofrio, A. D., & Russo, V. (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0037-1615261 · Cited by 52
Ischemic Stroke in an Obese Patient Receiving Dabigatran
Breuer, L., Ringwald, J., Schwab, S., & Köhrmann, M. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1215900 · Cited by 51
Evidence Gaps in the Era of Non–Vitamin K Oral Anticoagulants
Aronis, K. N., & Hylek, E. M. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007338 · Cited by 47
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease
Coppens, M., Weitz, J. I., & Eikelboom, J. W. (2019) · Circulation Research · doi:10.1161/circresaha.118.313141 · Cited by 42
Anticoagulation at the extremes of body weight: choices and dosing
McCaughan, G. J. B., Favaloro, E. J., Pasalic, L., & Curnow, J. L. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1517040 · Cited by 36
Safouris, A., Demulder, A., Triantafyllou, N. I., & Tsivgoulis, G. K. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.09.008 · Cited by 30
Lee, C., Lin, T., Chang, S., Chen, C.-H., Hsu, Y.-J., Hung, K., & Wen, M. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.277 · Cited by 29
Management of antithrombotic therapy in AF patients presenting with ACS and/or undergoing PCI
Lip, G. Y. H., Collet, J., Haude, M., & Huber, K. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy396 · Cited by 26
Mendoza, J. A., Silva, F., Rangel, L. M., Jaramillo, L., Mendoza, L., Garzon, J., & Quiroga, A. C. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196361 · Cited by 17
Cited by
Damluji, A. A., Forman, D. E., Wang, T. Y., Chikwe, J., Kunadian, V., Rich, M. W., Young, B. A., Page, R. L., DeVon, H. A., Alexander, K. P., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001112 · Cited by 348
Diagnosis and management of malnutrition in patients with heart failure
Esteban-Fernández, A., Villar-Taibo, R., Alejo, M., Arroyo, D., Bonilla Palomas, J. L., Cachero, M., Joaquin, C., Méndez Bailón, M., Pérez-Rivera, J. Á., Romero-Vigara, J. C., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093320 · Cited by 61
“Low body weight, as well as CKD and age, are factors limiting the dosage of direct-acting anticoagulants and must, therefore, be factored in when these drugs are prescribed [68].”
Background
Metadata
- Authors
- Chen, A., Stecker, E., & A. Warden, B.
- Venue
- Journal of the American Heart Association
- Published
- 2020-07-07
- Volume
- 9
- Issue
- 13
- Pages
- e017559-e017559
- ISSN
- 2047-9980 (ISSN-L)
- OpenAlex
- W3034331236
- Cited by
- 666
- References
- 94
- FWCI
- 40.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.